Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, multi-center, three arm randomized study to investigate the safety and efficacy on progression-free survival of RO5072759 + chlorambucil (GClb) compared to rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities

Next Previous
Trial Profile

An open-label, multi-center, three arm randomized study to investigate the safety and efficacy on progression-free survival of RO5072759 + chlorambucil (GClb) compared to rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obinutuzumab (Primary) ; Chlorambucil; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche

Most Recent Events

  • 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
  • 17 Jun 2022 Results meta-analysis of randomized controlled trials from NCT0101006, NCT01886872, NCT01056510, and NCT03336333, presented at the 27th Congress of the European Haematology Association
  • 07 Jun 2022 Results of meta-analysis of randomized controlled trials ((NCT01010061), ALLIANCE (NCT01886872), MABLE (NCT01056510), and SEQUOIA (NCT03336333)) assessing relative efficacy of zanubrutinib compared with standard frontline treatments for chronic lymphocytic leukemia, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top